SCHEMBL1644164

SCHEMBL1644164

Cc1cccc(C(O)c2ccncc2NC(=O)C(C)(C)C)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 1/20 0.47
▸ L3MBTL1 Q9Y468 1/20 0.47
▸ LMNA P02545 2/20 0.41
▸ ROCK2 O75116 1/20 0.41
▸ TSHR P16473 1/20 0.40
▸ IMPDH2 P12268 1/20 0.38
▸ SMN1; SMN2 Q16637 2/20 0.38
▸ PKM P14618 1/20 0.38
▸ KMT2A Q03164 1/20 0.38
▸ CYP3A4 P08684 2/20 0.37
▸ CYP2C9 P11712 2/20 0.37
▸ CYP1A2 P05177 1/20 0.37
▸ CYP2C19 P33261 1/20 0.37
▸ NT5E P21589 1/20 0.37
▸ KDM5A P29375 1/20 0.37
▸ MAPKAPK2 P49137 1/20 0.37
▸ KDM4E B2RXH2 1/20 0.36
▸ TBXA2R P21731 1/20 0.36
▸ HIF1A Q16665 1/20 0.36
▸ GAA P10253 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1643132 0.87 ALDH1A1 (0.48) ALDH1A1L3MBTL1ROCK2TSHRSMN1; SMN2
SCHEMBL1642548 0.87 TSHR (0.46) ALDH1A1L3MBTL1LMNATSHRSMN1; SMN2
SCHEMBL2076801 0.85 ALDH1A1 (0.66) ALDH1A1L3MBTL1ROCK2TSHRKMT2A
SCHEMBL2079331 0.78 ALDH1A1 (0.47) ALDH1A1L3MBTL1ROCK2TSHRSMN1; SMN2
SCHEMBL9846978 0.77 TSHR (0.46) ALDH1A1L3MBTL1TSHRSMN1; SMN2CYP3A4
SCHEMBL1642398 0.76 TSHR (0.44) ALDH1A1ROCK2TSHRSMN1; SMN2KMT2A
SCHEMBL1643191 0.75 KDM4E (0.46) ALDH1A1LMNATSHRSMN1; SMN2KMT2A
SCHEMBL1643897 0.74 KMT2A (0.40) ALDH1A1L3MBTL1TSHRKMT2AKDM4E
SCHEMBL16703053 0.74 KDM4C (0.48) LMNAROCK2SMN1; SMN2PKMKDM4E
SCHEMBL1643403 0.74 NT5E (0.47) ALDH1A1LMNATSHRSMN1; SMN2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110098298-A1 New Pyridin-3-Amine Derivatives LABORATORIOS ALMIRALL, S.A. (ES) 2011-04-28 — — US disclosed
EP-1987005-A2 NEW PYRIDIN-3-AMINE DERIVATIVES Laboratorios Almirall, S.A. (ES) 2008-11-05 — — EP disclosed
WO-2007096072-A2 NEW PYRIDIN-3-AMINE DERIVATIVES LABORATORIOS ALMIRALL, S.A. (ES) 2007-08-30 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110098298-A1 New Pyridin-3-Amine Derivatives MAPK1, MAP4K2, MAPK3 ALDH1A1 3124/4885L3MBTL1 4813/4885LMNA 1614/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback